Feed Top Reports Pricing

⌘K

08:17:54·23d

ANALYSTRating

Piper Sandler resumed coverage on Regeneron Pharma with a new price target

REGN· Regeneron Pharmaceuticals Inc.

Health Care

Original source

Companies

REGN
Regeneron Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Mar 31UpdatePiper Sandler$875.00
Mar 6UpdateBarclays$923.00
Jan 7UpdateBofA Securities$860.00
Dec 3UpdateMorgan Stanley$767.00
Nov 24UpdateTruist$798.00
Nov 24UpdateHSBC Securities$255.00

Related

PR8h
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
PR11h
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
PR1d
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
PR1d
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
PR2d
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
PR3d
Regeneron Announces Investor Conference Presentations
PR10d
Regeneron and Telix Announce Strategic Radiopharma Collaboration
PR10d
Telix and Regeneron Announce Strategic Radiopharma Collaboration

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022